Cape Biology: Some of the raised investment projects have been postponed until March 2027.

Kap Biotech announced that the company plans to postpone the "Anti-HPV Drug Development Project" and the "Nucleic Acid Molecular Diagnostic Product Development Project", with the expected date of achieving usability extended from March 2026 to March 2027. The planned investment for these two projects is 94 million yuan and 409 million yuan respectively, with a cumulative investment of 50.59 million yuan and 244 million yuan as of December 31, 2025. The reason for the delay is the longer research and clinical trial period and product development strategy adjustment. This matter has been approved by the board of directors and audit committee, with no objections from the independent directors or the sponsoring institution.